Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Screening and Recruitment Study in Adults Expressing Interest in the Emory Microbiota Enrichment Program (MEP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03350711
Recruitment Status : Recruiting
First Posted : November 22, 2017
Last Update Posted : January 31, 2019
Sponsor:
Information provided by (Responsible Party):
Colleen S Kraft, MD, MSc, Emory University

Brief Summary:
The goal of this study is to rapidly identify subjects who are eligible for the Microbiota Enrichment Program (MEP) at Emory in Atlanta, Georgia. This general screening protocol will be used to screen potential subjects for the Emory MEP and will be conducted at the Emory Clinic, the Hope Clinic of the Emory Vaccine Center and/or Emory affiliated hospitals. An electronic database will be created to capture demographic and medical information about individuals who are reaching out to obtain fecal microbiota transplant (FMT) and pre-screen these potential study participants for current and upcoming studies within MEP.

Condition or disease Intervention/treatment
Clostridium Difficile Infection Other: Microbiota Enrichment Program (MEP)

Detailed Description:

The unintended consequence of the development of life-saving antimicrobial therapies has been the havoc that is wreaked on the patient's intestinal microbiota. Clostridium difficile infection (CDI) has been found to be the causative agent of 15%-25% of all cases of antibiotic-associated diarrhea, with increasing severity in those with advanced age and who are hospitalized for other reasons. Despite resolution of symptoms in patients treated with antimicrobials, there remains an ~20% CDI recurrence rate. Furthermore, patients who experience a first recurrence have a 40% risk of an additional recurrence and those with two or more episodes face a 60% risk. As a result, there are substantial numbers of patients who live with chronic and debilitating diarrhea from CDI despite repeated courses of prolonged therapy. C. difficile infection represents an important clinical syndrome and development of new preventive and therapeutic strategies are a key unmet medical need.

Fecal microbiota transplant (FMT), which is defined as the transfer of the feces from one individual (donor) into another individual (recipient), has recently become more standardized and acceptable for the treatment of C. difficile. The first randomized controlled trial (RCT) was published in January of 2013 and compared duodenal infusion FMT after oral vancomycin as compared to oral vancomycin alone and for the treatment of recurrent C. difficile. The trial showed excellent efficacy for FMT, along with restoration of the diversity of the microbiota in the recipients. Even prior to this RCT, case series with over 200 patients had shown excellent efficacy with one FMT, with rates of success almost to 90% when patients received two FMTs.

Emory's Fecal Transplant Program was started in 2012, and since then has performed 280 FMTs in inpatient and outpatient settings. The Emory Microbiota Enrichment Program (MEP) came into existence in 2016 in order to provide a clinical research infrastructure to recruit subjects into clinical research studies related to the microbiome. The goal of this protocol is to create an electronic database capture with a survey to capture demographic and medical information about subjects reaching out to obtain FMT for a variety of reasons and, if needed, pre-screen these subjects for current and upcoming protocols within MEP. A list of potential participants will be generated using the Emory University Data Warehouse to identify subjects with CDI and other conditions that could benefit from the Emory MEP. Advertisements will be placed in the community as a recruitment tool and individuals that contact Emory will be connected to the study recruiter. The recruiters will review the eligibility criteria for inclusion in the MEP database as well as the inclusion and exclusion criteria for all of the enrolling FMT studies currently underway at the Hope Clinic and Emory University Hospitals. If the subject meets the inclusion criteria for one of the Emory FMT studies, they will be invited for a general screening visit or a study specific screening visit for a specific MEP protocol.

The duration of the study varies for each subject and participation is indefinite unless one of the following occurs:

  • A subject is rendered ineligible
  • The screening is completed, and a subject is referred to a specific MEP study.
  • A subject withdraws consent to participate in this study, which may be done verbally or by revocation letter. Additional details will be requested to determine if the participant either no longer wants to perform any MEP related activities (e.g., MEP survey) or revokes the future use of protected health information (PHI) and medical chart review during follow-up.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 200 participants
Observational Model: Case-Only
Time Perspective: Other
Target Follow-Up Duration: 10 Years
Official Title: A Screening and Recruitment Study in Adults Expressing Interest in the Emory Microbiota Enrichment Program
Actual Study Start Date : September 13, 2018
Estimated Primary Completion Date : January 2028
Estimated Study Completion Date : January 2028

Group/Cohort Intervention/treatment
Microbiota Enrichment Program (MEP)
Patients who are seeking a fecal microbiota transplant (FMT), for any reason, who will be part of a registry of patients to potentially screen for a FMT study.
Other: Microbiota Enrichment Program (MEP)

Registry participants will provide demographic and medical information and may take part in general screening procedures to facilitate enrolling into an appropriate FMT study.

Once determined to be eligible for study entry, study-specific screening procedures may include:

  • Health history and physical examination
  • Urinalysis
  • Urine or serum pregnancy test
  • Blood tests for Hepatitis B, Hepatitis C, HIV, chemistry panel (which includes liver function, kidney function), complete blood count with differential, platelet count, partial thromboplastin time (PTT), international normalized ratio (INR)
  • Electrocardiogram (EKG or ECG)
  • Stool studies

Participants will be re-screened every 6 months and will remain in follow-up indefinitely or until they are rendered ineligible, participate in a MEP study, or withdraw consent to be included in the database.





Primary Outcome Measures :
  1. To determine if the creation of a database will improve enrollment onto other research studies [ Time Frame: Ten years ]
    Successful creation of the database will be defined as capturing demographic and medical information about persons reaching out to obtain FMT in order to screen them for current and upcoming protocols within MEP.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Recruitment for this study will be done using Emory's data warehouse, subjects with a diagnosis of Clostridium difficile infection (CDI), or subjects that contact Emory with interest in FMT, as well as through referrals from local doctor's offices, and subjects who self-refer to the Emory Microbiota Enrichment Program (MEP)
Criteria

Inclusion Criteria:

  • Age of at least 18 years
  • Seeking services that are affiliated with the Emory Microbiota Enrichment Program (MEP) for any reason, such as:

    • Clinical services, interventions, or procedures (e.g., FMT), or
    • Research studies
  • Able to understand and approve the informed consent and HIPAA authorizations forms verbally on the phone or by signature in-person

Exclusion Criteria:

  • Known or suspected terminal disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03350711


Contacts
Layout table for location contacts
Contact: Colleen S Kraft, MD, MSc 678-487-9766 (OPT-4-TRY-POO) microbiota.enrichment@emory.edu
Contact: Jennifer Truell 404-778-0014 jennifer.carter.truell@emory.edu

Locations
Layout table for location information
United States, Georgia
Emory Clinic Recruiting
Atlanta, Georgia, United States, 30322
Contact: Jennifer Truell    404-778-0014    jennifer.carter.truell@emory.edu   
Contact: Allen W Graham    404-712-2962    allen.w.graham@emory.edu   
Emory Hospital Recruiting
Atlanta, Georgia, United States, 30322
Contact: Jennifer Truell    404-778-0014    jennifer.carter.truell@emory.edu   
Contact: Allen W Graham    404-712-2962    allen.w.graham@emory.edu   
The Hope Clinic of the Emory Vaccine Center Recruiting
Decatur, Georgia, United States, 30030
Contact: Jennifer Truell    404-778-0014    jennifer.carter.truell@emory.edu   
Contact: Allen W Graham    404-712-2962    allen.w.graham@emory.edu   
Sponsors and Collaborators
Emory University
Investigators
Layout table for investigator information
Principal Investigator: Colleen Kraft, MD, MSc Emory University

Additional Information:

Layout table for additonal information
Responsible Party: Colleen S Kraft, MD, MSc, Associate Professor, Emory University
ClinicalTrials.gov Identifier: NCT03350711     History of Changes
Other Study ID Numbers: IRB00098240
First Posted: November 22, 2017    Key Record Dates
Last Update Posted: January 31, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Colleen S Kraft, MD, MSc, Emory University:
Microbiota composition
Microbiota Enrichment Program
Fecal microbiota transplant (FMT)

Additional relevant MeSH terms:
Layout table for MeSH terms
Clostridium Infections
Gram-Positive Bacterial Infections
Bacterial Infections